目的 探讨符合线路SPECT 18F-FDG代谢显像在恶性淋巴瘤临床分期和疗效判断的临床应用价值.方法 我们对8例非霍奇金病(NHL)病人进行18 F-FDG 符合线路SPECT显像,用定性和半定量方法进行分析,并进行随访.结果 8例病人中首次进行18F-FDG显像2例结果阴性,6 例阳性.1例病人化疗后出现FDG摄取阳性(T/B=2.39),病理证实NHL转移,改变了临床分期;3例病人在化疗前后进行两次18F-FDG显像,FDG摄取由阳性转为阴性,治疗有效;2例病人化疗后FDG摄取阴性,疗效稳定.结论 本法对恶性淋巴瘤的分期和疗效判断不失为一种有用的检测手段.
Objective To investigate the value and its clinical application for staging and evaluating the therapeutic effectiveness of lymphoma using 18F-FDG SPECT with coincidence detection metabolic imaging. Methods Eight patients underwent 18F-FDG metabolic imaging. Analysis was made in qualitative and semi-quantitative ways. Results Among them Two patients were negative while Six patients were positive. One patient showed positive(T/B = 2.39) after chemotherapy, pathologically proving to be metastasis of NHL, which led to change clinical staging; Three patient had 18F-FDG imaging before and after chemotherapy, the 18F-FDG imaging became negative after chemotherapy which verified the effectiveness of the therapy; Still One patient was negative after chemotherapy which showed that the effectiveness was steady. Conclusion 18F-FDG imaging appears to be very useful for staging and evaluating the therapeutic effectiveness of lymphoma.